{"id":54426,"date":"2023-03-02T14:05:41","date_gmt":"2023-03-02T13:05:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/"},"modified":"2023-03-02T14:05:41","modified_gmt":"2023-03-02T13:05:41","slug":"lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/","title":{"rendered":"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023"},"content":{"rendered":"
\n

CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX<\/a> #LineageCellTherapeutics<\/a>—Lineage Cell Therapeutics, Inc.<\/a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 9, 2023, at 4:30 p.m. Eastern Time\/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2022 financial and operating results and to provide a business update.\n<\/p>\n

<\/a><\/p>\n

\nInterested parties may access the conference call on March 9th<\/sup>, 2023, by dialing (800) 715-9871 from the U.S. and Canada and should request the \u201cLineage Cell Therapeutics Call\u201d. A live webcast of the conference call will be available online in the Investors<\/a> section of Lineage\u2019s website. A replay of the webcast will be available on Lineage\u2019s website for 30 days and a telephone replay will be available through March 16, 2023, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 5707771.\n<\/p>\n

\nAbout Lineage Cell Therapeutics, Inc.<\/b>\n<\/p>\n

\nLineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage\u2019s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage\u2019s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic (\u201coff-the-shelf\u201d) product candidates: (i) OpRegen\u00ae<\/sup>, a retinal pigment epithelial cell therapy in Phase 2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed<\/a> under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1\/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage\u2019s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com<\/a> or follow the company on Twitter @LineageCell<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nLineage Cell Therapeutics, Inc. IR<\/b>
Ioana C. Hone
\n
(ir@lineagecell.com<\/a>)
\n
(442) 287-8963\n<\/p>\n

\nLifeSci Advisors<\/b>
Daniel Ferry
\n
(daniel@lifesciadvisors.com<\/a>)
\n
(617) 430-7576\n<\/p>\n

\nRusso Partners \u2013 Media Relations<\/b>
Nic Johnson or David Schull
\n
(Nic.johnson@russopartnersllc.com<\/a>)
\n
(David.schull@russopartnersllc.com<\/a>)
\n
(212) 845-4242\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets. Lineage … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54426","6":"format-standard","7":"category-industry"},"yoast_head":"\nLineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets. Lineage ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-02T13:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230302005045\/en\/1726458\/21\/LINEAGE_2023_RGB_JPG_1740x360.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023\",\"datePublished\":\"2023-03-02T13:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/\"},\"wordCount\":496,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005045\\\/en\\\/1726458\\\/21\\\/LINEAGE_2023_RGB_JPG_1740x360.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/\",\"name\":\"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005045\\\/en\\\/1726458\\\/21\\\/LINEAGE_2023_RGB_JPG_1740x360.jpg\",\"datePublished\":\"2023-03-02T13:05:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005045\\\/en\\\/1726458\\\/21\\\/LINEAGE_2023_RGB_JPG_1740x360.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230302005045\\\/en\\\/1726458\\\/21\\\/LINEAGE_2023_RGB_JPG_1740x360.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/","og_locale":"en_US","og_type":"article","og_title":"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 - Pharma Trend","og_description":"CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets. Lineage ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-02T13:05:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230302005045\/en\/1726458\/21\/LINEAGE_2023_RGB_JPG_1740x360.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023","datePublished":"2023-03-02T13:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/"},"wordCount":496,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230302005045\/en\/1726458\/21\/LINEAGE_2023_RGB_JPG_1740x360.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/","url":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/","name":"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230302005045\/en\/1726458\/21\/LINEAGE_2023_RGB_JPG_1740x360.jpg","datePublished":"2023-03-02T13:05:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230302005045\/en\/1726458\/21\/LINEAGE_2023_RGB_JPG_1740x360.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230302005045\/en\/1726458\/21\/LINEAGE_2023_RGB_JPG_1740x360.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lineage-cell-therapeutics-to-report-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-9-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54426"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54426\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}